A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme
Status:
Active, not recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This clinical trial evaluates adding high-dose ascorbate (vitamin C) to standard of care
treatment of glioblastoma multiforme (a type of brain tumor) in adults. All subjects will
receive high-dose ascorbate in addition to the standard treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Bryan Allen University of Iowa
Collaborators:
Holden Comprehensive Cancer Center National Cancer Institute (NCI)